Adam Walsh
Stock Analyst at Roth Capital
(2.71)
# 2,351
Out of 5,182 analysts
18
Total ratings
62.5%
Success rate
18.98%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Adam Walsh
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EQ Equillium | Reiterates: Buy | $12 | $2.05 | +485.37% | 2 | Apr 17, 2026 | |
| INSM Insmed | Reiterates: Buy | $212 | $134.94 | +57.11% | 2 | Apr 17, 2026 | |
| APLS Apellis Pharmaceuticals | Initiates: Buy | $31 | $40.99 | -24.37% | 1 | Mar 13, 2026 | |
| VTVT vTv Therapeutics | Initiates: Buy | $58 | $31.97 | +81.42% | 1 | Jan 23, 2026 | |
| ASND Ascendis Pharma | Maintains: Buy | $146 → $171 | $222.08 | -23.00% | 3 | Apr 20, 2020 | |
| GLPG Galapagos NV | Maintains: Buy | $121 → $188 | $28.43 | +561.27% | 4 | Jul 15, 2019 | |
| CORT Corcept Therapeutics | Downgrades: Hold | n/a | $46.62 | - | 4 | May 31, 2018 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Buy | $74 → $77 | $24.53 | +213.90% | 1 | Apr 18, 2018 |
Equillium
Apr 17, 2026
Reiterates: Buy
Price Target: $12
Current: $2.05
Upside: +485.37%
Insmed
Apr 17, 2026
Reiterates: Buy
Price Target: $212
Current: $134.94
Upside: +57.11%
Apellis Pharmaceuticals
Mar 13, 2026
Initiates: Buy
Price Target: $31
Current: $40.99
Upside: -24.37%
vTv Therapeutics
Jan 23, 2026
Initiates: Buy
Price Target: $58
Current: $31.97
Upside: +81.42%
Ascendis Pharma
Apr 20, 2020
Maintains: Buy
Price Target: $146 → $171
Current: $222.08
Upside: -23.00%
Galapagos NV
Jul 15, 2019
Maintains: Buy
Price Target: $121 → $188
Current: $28.43
Upside: +561.27%
Corcept Therapeutics
May 31, 2018
Downgrades: Hold
Price Target: n/a
Current: $46.62
Upside: -
Ultragenyx Pharmaceutical
Apr 18, 2018
Maintains: Buy
Price Target: $74 → $77
Current: $24.53
Upside: +213.90%